Evidence-based insights into peptide protocols, safety research, and optimization strategies. Built on clinical rigor, powered by community knowledge.
Get weekly insights on peptide protocols, safety updates, and optimization strategies delivered to your inbox.
No spam. Unsubscribe anytime. Clinical rigor, always.
Deep dives into peptide science — evidence-graded, honestly reported
A research-driven breakdown of what's actually inside the most popular peptide blend — and why fixed ratios create pharmacological problems your supplier won't mention.
Inside the KLOW quad stack: GHK-Cu, BPC-157, TB-500, and KPV. We examine the pharmacokinetic mismatches, the missing human trials, and why individual titration beats fixed-ratio convenience.
Comprehensive outcome research with safety data and practical protocol references
Detailed compound profiles with mechanisms, safety data, and dosing protocols
How a fragment of growth hormone is rewriting the rules of targeted fat loss — and why the FDA just pulled the plug.
AOD 9604 isolates the fat-burning signal of growth hormone while leaving the growth-promoting pathways untouched. Five surprising truths about the peptide the FDA reclassified overnight.
A selective ghrelin mimetic that triggers your pituitary to release growth hormone without touching cortisol, prolactin, or appetite.
Ipamorelin is a synthetic pentapeptide and the first truly selective growth hormone secretagogue. It binds the GHS-R1a receptor to trigger pulsatile GH release without the hormonal side-channel activation that defined earlier peptides like GHRP-6.
35+
Articles
18
Categories